BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 26450987)

  • 1. Memory B-cell reconstitution following allogeneic hematopoietic stem cell transplantation is an EBV-associated transformation event.
    Burns DM; Tierney R; Shannon-Lowe C; Croudace J; Inman C; Abbotts B; Nagra S; Fox CP; Chaganti S; Craddock CF; Moss P; Rickinson AB; Rowe M; Bell AI
    Blood; 2015 Dec; 126(25):2665-75. PubMed ID: 26450987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EBV and memory B cells: an affair with consequences.
    Khanna R
    Blood; 2015 Dec; 126(25):2655-6. PubMed ID: 26679540
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation.
    Ruf S; Behnke-Hall K; Gruhn B; Bauer J; Horn M; Beck J; Reiter A; Wagner HJ
    J Clin Virol; 2012 Mar; 53(3):186-94. PubMed ID: 22182950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.
    van Esser JW; van der Holt B; Meijer E; Niesters HG; Trenschel R; Thijsen SF; van Loon AM; Frassoni F; Bacigalupo A; Schaefer UW; Osterhaus AD; Gratama JW; Löwenberg B; Verdonck LF; Cornelissen JJ
    Blood; 2001 Aug; 98(4):972-8. PubMed ID: 11493441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-Hematopoietic Stem Cell Transplantation Rituximab for Epstein-Barr Virus and Post-Lymphoproliferative Disorder Prophylaxis in Alemtuzumab Recipients.
    Patel C; Pasciolla M; Abramova R; Salerno D; Gomez-Arteaga A; Shore TB; Orfali N; Mayer S; Hsu J; Phillips AA; Chaekal OK; Satlin MJ; Soave R; Kodiyanplakkal RPL; Drelick A; Plate M; Besien KV
    Transplant Cell Ther; 2023 Feb; 29(2):132.e1-132.e5. PubMed ID: 36334653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus (EBV) load in cerebrospinal fluid and peripheral blood of patients with EBV-associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation.
    Liu QF; Ling YW; Fan ZP; Jiang QL; Sun J; Wu XL; Zhao J; Wei Q; Zhang Y; Yu GP; Wu MQ; Feng R
    Transpl Infect Dis; 2013 Aug; 15(4):379-92. PubMed ID: 23692640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epstein-Barr virus persistence in the absence of conventional memory B cells: IgM+IgD+CD27+ B cells harbor the virus in X-linked lymphoproliferative disease patients.
    Chaganti S; Ma CS; Bell AI; Croom-Carter D; Hislop AD; Tangye SG; Rickinson AB
    Blood; 2008 Aug; 112(3):672-9. PubMed ID: 18509091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of Epstein-Barr virus-lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation.
    van Esser JW; Niesters HG; van der Holt B; Meijer E; Osterhaus AD; Gratama JW; Verdonck LF; Löwenberg B; Cornelissen JJ
    Blood; 2002 Jun; 99(12):4364-9. PubMed ID: 12036863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of plasma and peripheral blood mononuclear cells Epstein-Barr Virus DNA dynamics on prognosis of allogeneic stem cell transplantation.
    Zhou X; Lu X; He J; Xu Z; Li Q; Ye P; Zhong Z; Shi W; Yan H; You Y; Hu Y; Wang H
    Front Cell Infect Microbiol; 2022; 12():980113. PubMed ID: 36189344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.
    Dolcetti R
    Autoimmun Rev; 2007 Dec; 7(2):96-101. PubMed ID: 18035317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of use of Epstein-Barr viral load in patients after allogeneic stem cell transplantation to diagnose and monitor posttransplant lymphoproliferative disease.
    Gärtner BC; Schäfer H; Marggraff K; Eisele G; Schäfer M; Dilloo D; Roemer K; Laws HJ; Sester M; Sester U; Einsele H; Mueller-Lantzsch N
    J Clin Microbiol; 2002 Feb; 40(2):351-8. PubMed ID: 11825941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid reconstitution of Epstein-Barr virus-specific T lymphocytes following allogeneic stem cell transplantation.
    Marshall NA; Howe JG; Formica R; Krause D; Wagner JE; Berliner N; Crouch J; Pilip I; Cooper D; Blazar BR; Seropian S; Pamer EG
    Blood; 2000 Oct; 96(8):2814-21. PubMed ID: 11023516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
    Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of different rabbit ATG preparation effects on early lymphocyte subset recovery after allogeneic HSCT and its association with EBV-mediated PTLD.
    Mensen A; Na IK; Häfer R; Meerbach A; Schlecht M; Pietschmann ML; Gruhn B
    J Cancer Res Clin Oncol; 2014 Nov; 140(11):1971-80. PubMed ID: 24962343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical risks analysis of EBV infection in patients with allogeneic hematopoietic stem cell transplantation].
    Bao X; Zhu Q; Qiu H; Chen F; Xue S; Ma X; Sun A; Wu D
    Zhonghua Xue Ye Xue Za Zhi; 2016 Feb; 37(2):138-43. PubMed ID: 27014984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
    Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
    Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful preemptive therapy with single-dose rituximab for Epstein-Barr virus infection to prevent post-transplant lymphoproliferative disease after pediatric hematopoietic stem cell transplantation.
    Kim BK; Kang HJ; Hong KT; An HY; Choi JY; Lee JS; Park SS; Shin HY
    Transpl Infect Dis; 2019 Dec; 21(6):e13182. PubMed ID: 31556214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
    Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
    Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation].
    Niu YY; Dong YJ; Yin Y; Xu WL; Liang ZY; Wang Q; Li Y; Liu W; Ou JP; Ren HY
    Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):904-910. PubMed ID: 35045651
    [No Abstract]   [Full Text] [Related]  

  • 20. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
    Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
    Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.